Eyenovia is the Optejet® company

NASDAQ: EYEN

A public eye care company focused on improving the usability and administration of eye medications with our Optejet® device for use by our patients and their caregivers.

The Optejet® is the only FDA-approved ophthalmic spray alternative to eye drops.

Pipeline

Our pipeline candidates are designed to address the issues of conventional eye drop bottles delivering the appropriate dose and a better patient experience. More

MicroPine

Eyenovia’s lead pipeline candidate is MicroPine for the prevention of myopia progression in children. If approved, MicroPine will be the first drug-device combination product for this condition. The Optejet could enable more children to self-administer atropine. More

Latest News

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

Accessibility

If you require assistance accessing this site, please contact Eyenovia at (833) 393-6684 Extension 1